SPKB

15-12G - Silver Spike Acquisition Corp II (0001826435) (Filer)

25-NSE - Silver Spike Acquisition Corp II (0001826435) (Subject)

8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)

Silver Spike Acquisition Corp II (the "Company") today announced that it will redeem all of its outstanding Class A ordinary shares (the "Class A Ordinary Shares"), effective as of March 27, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (the "Articles"). As stated in the Company's Articles, if the Company does not consummate an initial business combination within 24 months of the closing of the Company's initial public offering, or March 15, 2023, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably poss

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Silver Spike Acquisition Corp II (the "Company") today announced that it will redeem all of its outstanding Class A ordinary shares (the "Class A Ordinary Shares"), effective as of March 27, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (the "Articles"). As stated in the Company's Articles, if the Company does not consummate an initial business combination within 24 months of the closing of the Company's initial public offering, or March 15, 2023, the Company will: (i) cease all operations except for the purpose of

8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)

8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)

DEF 14A - Silver Spike Acquisition Corp II (0001826435) (Filer)

SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)

SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)

SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)

SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)

PRE 14A - Silver Spike Acquisition Corp II (0001826435) (Filer)

SC 13G/A - Silver Spike Acquisition Corp II (0001826435) (Subject)

SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)

10-Q - Silver Spike Acquisition Corp II (0001826435) (Filer)

8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)

10-Q - Silver Spike Acquisition Corp II (0001826435) (Filer)

SC 13G - Silver Spike Acquisition Corp II (0001826435) (Subject)

8-K - Silver Spike Acquisition Corp II (0001826435) (Filer)

Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II (“Silver Spike II” or “SPKB”) (NASDAQ:SPKB), a publicly traded special purpose acquisition company (“SPAC”), today announced that they have mutually agreed to terminate their previously announced agreement and plan of merger (the “Business Combination Agreement”), effective immediately, as a result of current unfavorable market conditions. Silver Spike II intends to continue in its efforts to identify a prospective target business for an initial business combination. Additional information about the termination of the Business Combination Agree

Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II ("Silver Spike II" or "SPKB") (NASDAQ:SPKB), a publicly traded special purpose acquisition company ("SPAC"), today announced that they have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately, as a result of current unfavorable market conditions. Silver Spike II intends to continue in its efforts to identify a prospective target business for an initial business combination. Additional information about the termination of the Business Combination Agre

10-Q - Silver Spike Acquisition Corp II (0001826435) (Filer)

CEO and founder of psychedelics company Eleusis, Shlomi Raz has extensive experience in managing companies. With a BS in Finance and a later an MA in Psychology, Raz became a vice president at JP Morgan (NYSE:JPM) and managing director at Goldman Sachs (NYSE:GS). In 2013, he founded Eleusis (NASDAQ:ELEU), which he still manages today, after the merger with the Silver Spike Acquisition Corp. II (NASDAQ:SPKB). In June 2020, when Eleusis was still a private company, Raz took part in a Psyched Studio-hosted conference, where he talked about the difficulties psychedelics currently encounter in becoming viable therapeutic options. Raz oversees the company’s corporate and clinical development